HDL and cognition in neurodegenerative disorders

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 22-36

  Hottman, David A ^a   Chernick, Dustin ^a   Cheng, Shaowu ^a   Wang, Zhe ^a   Li, Ling ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; ANACETRAPIB; APABETALONE; APOLIPOPROTEIN A1; BEXAROTENE; CHOLESTEROL; DALCETRAPIB; EVACETRAPIB; FIBRIC ACID DERIVATIVE; GALANTAMINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LXR 623; MK 1903; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; NICOTINIC ACID; NICOTINIC AGENT; PEPTIDOMIMETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RIVASTIGMINE; TORCETRAPIB; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ORPHAN NUCLEAR RECEPTOR;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL TRANSPORT; COGNITION; DEGENERATIVE DISEASE; DRUG INFUSION; GENETIC ASSOCIATION; GENETIC RISK; HERBAL MEDICINE; HUMAN; HUNTINGTON CHOREA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION; ANIMAL; BRAIN; FEMALE; LIVER; MALE; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL, HDL; COGNITION; FEMALE; HUMANS; HUNTINGTON DISEASE; LIPOPROTEINS, HDL; LIVER; MALE; NEURODEGENERATIVE DISEASES; ORPHAN NUCLEAR RECEPTORS; PARKINSON DISEASE;

EID: 84909636151     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.07.015     Document Type: Review

References (246)

1. Akhmedova S.N., et al. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 2001, 184:179-182.
2. Akhondzadeh S., et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 2003, 28:53-59.
3. Albers J.J., et al. Cholesteryl ester transfer protein in human brain. Int. J. Clin. Lab. Res. 1992, 21:264-266.
4. Albers J.J., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 2013, 62:1575-1579.
5. Alzheimer's Association 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208-245.
6. Anantharamaiah G.M., et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 1985, 260:10248-10255.
7. Atrahimovich D., et al. Glabridin protects paraoxonase 1 from linoleic acid hydroperoxide inhibition via specific interaction: a fluorescence-quenching study. J. Agric. Food Chem. 2012, 60:3679-3685.
8. Atrahimovich D., et al. The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study. Bioorg. Med. Chem. 2013, 21:3348-3355.
9. Atzmon G., et al. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M712-M715.
10. Atzmon G., et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol. 2006, 4:e113.
11. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37:1304-1316.
12. Bailey D., et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 2010, 55:2580-2589.
13. Barter P.J., et al. Antiinflammatory properties of HDL. Circ. Res. 2004, 95:764-772.
14. Barter P.J., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
15. Barzilai N., et al. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 2006, 67:2170-2175.
16. Bergman A.J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J. Clin. Pharmacol. 2004, 44:1054-1062.
17. Bloedon L.T., et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 2008, 49:1344-1352.
18. Boatman P.D., et al. (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. J. Med. Chem. 2012, 55:3644-3666.
19. Bonarek M., et al. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000, 19:141-148.
20. Brunham L.R., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 2006, 116:1052-1062.
21. Buchanan D.D., et al. Association of APOE with Parkinson disease age-at-onset in women. Neurosci. Lett. 2007, 411:185-188.
22. Buga G.M., et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J. Lipid Res. 2006, 47:2148-2160.
23. Burns M.P., et al. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J. Neurochem. 2006, 98:792-800.
24. Bussell R., Eliezer D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 2003, 329:763-778.
25. Byrne S., et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012, 11:232-240.
26. Cam J.A., Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegener. 2006, 1:8.
27. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 2005, 258:94-114.
28. Caselli R.J., et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 2009, 361:255-263.
29. Cassani E., et al. Cardiometabolic factors and disease duration in patients with Parkinson's disease. Nutrition 2013, 29:1331-1335.
30. Castellano J.M., et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011, 3. (89ra57).
31. Cereda E., et al. Low cardiometabolic risk in Parkinson's disease is independent of nutritional status, body composition and fat distribution. Clin. Nutr. 2012, 31:699-704.
32. Chen S., et al. Genetics of amyotrophic lateral sclerosis: an update. Mol. Neurodegener. 2013, 8:28.
33. Cockerill G.W., et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
34. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
35. Corder E.H., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
36. Costet P., et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275:28240-28245.
37. Cramer P.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
38. Cui Y.M., et al. Effect of glabridin from Glycyrrhiza glabra on learning and memory in mice. Planta Med. 2008, 74:377-380.
39. D'Amico E., et al. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013, 65:509-527.
40. Datta G., et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 2001, 42:1096-1104.
41. Davidson M.H., Toth P.P. High-density lipoprotein metabolism: potential therapeutic targets. Am. J. Cardiol. 2007, 100:n32-n40.
42. Dedic S.I., et al. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis?. Neurol. Res. 2012, 34:576-580.
43. DeJesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
44. Demeester N., et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 2000, 41:963-974.
45. Diditchenko S., et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2202-2211.
46. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
47. Donkin J.J., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem. 2010, 285:34144-34154.
48. Donmez G., Outeiro T.F. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol. Med. 2013, 5:344-352.
49. Dupuis L., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008, 70:1004-1009.
50. Durairajan S.S., et al. Berberine ameliorates beta-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol. Aging 2012, 33:2903-2919.
51. Elbaz A., et al. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 2002, 55:25-31.
52. Escola-Gil J.C., et al. Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport in vivo. Transl. Res. 2013, 161:110-117.
53. Fagan A.M., et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol. 2000, 48:201-210.
54. Fagan A.M., et al. ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am. J. Pathol. 2004, 165:1413-1422.
55. Farnier M., et al. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Curr. Med. Res. Opin. 2011, 27:2165-2173.
56. Federoff M., et al. A large study reveals no association between APOE and Parkinson's disease. Neurobiol. Dis. 2012, 46:389-392.
57. Fitz N.F., et al. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 2010, 30:6862-6872.
58. Fitz N.F., et al. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J. Neurosci. 2012, 32:13125-13136.
59. Fitz N.F., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340. (924-c).
60. Franceschini G., et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 1980, 66:892-900.
61. Gao J., et al. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol. Aging 2011, 32:2106. (e1-6).
62. Getz G.S., Reardon C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1104-1115.
63. Getz G.S., et al. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr. Pharm. Des. 2010, 16:3173-3184.
64. Goldstein L.H., Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013, 12:368-380.
65. Gotto A.M., et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am. J. Cardiol. 2014, 113:76-83.
66. Gregorio M.L., et al. Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson's disease. Biomed. Res. Int. 2013, 2013. (641515).
67. Group, A.S., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362:1563-1574.
68. Group, H.T.C. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
69. Guo J., et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am. J. Cardiol. 2012, 110:1296-1301.
70. Gusella J.F., MacDonald M.E. Huntington's disease: the case for genetic modifiers. Genome Med. 2009, 1:80.
71. Gusella J.F., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238.
72. Haass C., et al. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012, 2:a006270.
73. Haidar B., et al. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J. Biol. Chem. 2004, 279:9963-9969.
74. Handattu S.P., et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34:525-534.
75. Hasanein P. Glabridin as a major active isoflavan from Glycyrrhiza glabra (licorice) reverses learning and memory deficits in diabetic rats. Acta Physiol. Hung. 2011, 98:221-230.
76. Herrschaft H., et al. Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240mg. J. Psychiatr. Res. 2012, 46:716-723.
77. Hirsch-Reinshagen V., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 2005, 280:43243-43256.
78. Holtzman D.M., et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006312.
79. Huang X., et al. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004, 62:2198-2202.
80. Ikeda K., et al. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Neurodegener. Dis. 2011, 8:252-258.
81. Inamori T., et al. The combined effects of genetic variation in the SIRT1 gene and dietary intake of n-3 and n-6 polyunsaturated fatty acids on serum LDL-C and HDL-C levels: a population based study. Lipids Health Dis. 2013, 12(4).
82. Investigators A.-H. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial. Am. Heart J. 2011, 161:538-543.
83. Investigators A.-H., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365:2255-2267.
84. Ito J., et al. Differential generation of high-density lipoprotein by endogenous and exogenous apolipoproteins in cultured fetal rat astrocytes. J. Neurochem. 1999, 72:2362-2369.
85. Ito J., et al. Apolipoprotein A-I induces translocation of cholesterol, phospholipid, and caveolin-1 to cytosol in rat astrocytes. J. Biol. Chem. 2002, 277:7929-7935.
86. Ito J., et al. Apolipoprotein A-I induces translocation of protein kinase C[alpha] to a cytosolic lipid-protein particle in astrocytes. J. Lipid Res. 2004, 45:2269-2276.
87. Izaks G.J., et al. Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive function in persons aged 35years or older. Neurobiol. Aging 2012, 33:1851. (e7-16).
88. Jawaid A., et al. Does apolipoprotein E genotype modify the clinical expression of ALS?. Eur. J. Neurol. 2011, 18:618-624.
89. Ji W., Gong B.Q. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J. Ethnopharmacol. 2007, 113:318-324.
90. Jiang Q., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
91. Jorgensen A.B., et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014, 371:32-41.
92. Kanekiyo T., et al. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
93. Karasinska J.M., Hayden M.R. Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 2011, 7:561-572.
94. Kawano M., et al. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin. Chim. Acta 1995, 239:209-211.
95. Kay A.D., et al. Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury. J. Neurotrauma 2003, 20:717-723.
96. Keeney J.T., et al. Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin. Appl. 2013, 7:109-122.
97. Kehoe P., et al. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet. 1999, 36:108-111.
98. Kim S.H., Park K.S. Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol. Res. 2003, 48:511-513.
99. Koch S., et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 2001, 42:1143-1151.
100. Koldamova R.P., et al. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40:3553-3560.
101. Koldamova R., et al. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 2005, 280:43224-43235.
102. Koldamova R.P., et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 2005, 280:4079-4088.
103. Kondo I., Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 1998, 806:271-273.
104. Kurz M.W., et al. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J. Geriatr. Psychiatry Neurol. 2009, 22:166-170.
105. LaClair K.D., et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener. 2013, 8:18.
106. LaFerla F.M., Green K.N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
107. Landreth G.E., et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340. (924-g).
108. Launer L.J., et al. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001, 57:1447-1452.
109. Lauring B., et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 2012, 4:148ra115.
110. Lee T.S., et al. Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J. Cell. Biochem. 2010, 111:104-110.
111. Lees A.J., et al. Parkinson's disease. Lancet 2009, 373:2055-2066.
112. Lefterov I., et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 2010, 285:36945-36957.
113. Leman L.J., et al. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J. Med. Chem. 2014, 57:2169-2196.
114. Leoni V., et al. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol. Dis. 2013, 55:37-43.
115. Lewis T.L., et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285:36958-36968.
116. Li X., et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 28:91-106.
117. Li H., et al. Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 2013, 33:687-693.
118. Linton M.F., et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 1991, 88:270-281.
119. Liu X., et al. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRalpha and PPARalpha transcriptional programs. Endocr. J. 2010, 57:881-893.
120. Lopez M., et al. Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov. Disord. 2007, 22:417-420.
121. Maher P., et al. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. 2011, 20:261-270.
122. Mahley R.W., Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 2012, 76:871-885.
123. Mawuenyega K.G., et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
124. McKenney J. Niacin for dyslipidemia: considerations in product selection. Am. J. Health Syst. Pharm. 2003, 60:995-1005.
125. McLure K.G., et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One 2013, 8:e83190.
126. Merched A., et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 2000, 21:27-30.
127. Mineo C., et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003, 278:9142-9149.
128. Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis. Lancet 2007, 369:2031-2041.
129. Mockel B., et al. Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J. Neurochem. 1994, 62:788-798.
130. Morley J.F., et al. Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 2012, 27:512-518.
131. Morrison A.C., et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat. Genet. 2013, 45:899-901.
132. Navab M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 2000, 41:1481-1494.
133. Navab M., et al. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1325-1331.
134. Navab M., et al. The double jeopardy of HDL. Ann. Med. 2005, 37:173-178.
135. Nicholls S.J., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306:2099-2109.
136. Nicholls S.J., et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc. Drugs Ther. 2012, 26:181-187.
137. Nissen S.E., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
138. O'Connell B.J., Genest J. High-density lipoproteins and endothelial function. Circulation 2001, 104:1978-1983.
139. Oram J.F., Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 2005, 85:1343-1372.
140. Paganoni S., et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011, 44:20-24.
141. Panas M., et al. Apolipoprotein E and presenilin-1 genotypes in Huntington's disease. J. Neurol. 1999, 246:574-577.
142. Pankratz N., et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov. Disord. 2006, 21:45-49.
143. Panzenboeck U., et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J. Biol. Chem. 2002, 277:42781-42789.
144. Park S.H., et al. Sage weed (Salvia plebeia) extract antagonizes foam cell formation and promotes cholesterol efflux in murine macrophages. Int. J. Mol. Med. 2012, 30:1105-1112.
145. Pasinetti G.M., et al. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 2011, 232:1-6.
146. Patel S., et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010, 212:392-397.
147. Paterno R., et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc. Dis. 2004, 17:204-211.
148. Perry E., Howes M.J. Medicinal plants and dementia therapy: herbal hopes for brain aging?. CNS Neurosci. Ther. 2011, 17:683-698.
149. Picaud S., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19754-19759.
150. Pierce L.R., et al. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
151. Pitas R.E., et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J. Biol. Chem. 1987, 262:14352-14360.
152. Poirier J., et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
153. Pollin T.I., et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
154. Praline J., et al. APOE epsilon4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. Eur. J. Neurol. 2011, 18:1046-1052.
155. Price A.R., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340. (924-d).
156. Pringsheim T., et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord. 2012, 27:1083-1091.
157. Prueksaritanont T., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 2002, 301:1042-1051.
158. Pulkes T., et al. Association between apolipoprotein E genotypes and Parkinson's disease. J. Clin. Neurosci. 2011, 18:1333-1335.
159. Qiang J.K., et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann. Neurol. 2013, 74:119-127.
160. Rader D.J., deGoma E.M. Future of cholesteryl ester transfer protein inhibitors. Annu. Rev. Med. 2014, 65:385-403.
161. Ramprasath V.R., Jones P.J. Anti-atherogenic effects of resveratrol. Eur. J. Clin. Nutr. 2010, 64:660-668.
162. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J. Alzheimers Dis. 2012, 30(Suppl. 2):S127-S145.
163. Reitz C., et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 2004, 61:705-714.
164. Reitz C., et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol. 2010, 67:1491-1497.
165. Riddell D.R., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
166. Rogers R.L., et al. Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology 1989, 40:260-269.
167. Rosenthal S.L., Kamboh M.I. Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr. Genet. Med. Rep. 2014, 2:85-101.
168. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
169. Saczynski J.S., et al. The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am. J. Epidemiol. 2007, 165:985-992.
170. Saeed M., et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 2006, 67:771-776.
171. Saft C., et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:1692-1696.
172. Sagare A.P., et al. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
173. Saito K., et al. Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury. Biochem. J. 1997, 321(Pt 1):145-149.
174. Sanders A.E., et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010, 303:150-158.
175. Scheuner D., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
176. Schiepers O.J., et al. APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol. Psychiatry 2012, 17:315-324.
177. Schrag M., et al. Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol. Dis. 2013, 59:100-110.
178. Schwartz G.G., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012, 367:2089-2099.
179. Scigliano G., et al. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006, 37:1184-1188.
180. Scigliano G., et al. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat. Disord. 2009, 15:138-143.
181. Segrest J.P., et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res. 1992, 33:141-166.
182. Segrest J.P., et al. The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv. Protein Chem. 1994, 45:303-369.
183. Segrest J.P., et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr. Opin. Lipidol. 2000, 11:105-115.
184. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
185. Shirali S., et al. Effect of crocin on the insulin resistance and lipid profile of streptozotocin-induced diabetic rats. Phytother. Res. 2013, 27:1042-1047.
186. Singh-Manoux A., et al. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1556-1562.
187. Small S.A., Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 2006, 52:15-31.
188. Smith C.E., et al. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009, 4:e5465.
189. Smythies L.E., et al. Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am. J. Physiol. Cell Physiol. 2010, 298:C1538-C1548.
190. Snell R.G., et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 1993, 4:393-397.
191. Song F., et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 2012, 7:e34078.
192. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
193. Staels B., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
194. Staffa J.A., et al. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002, 346:539-540.
195. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 1996, 19:53-77.
196. Stukas S., et al. The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1. Biochim. Biophys. Acta 2012, 1821:536-546.
197. Stukas S., et al. High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. Cell Metab. 2014, 19:574-591.
198. Sutedja N.A., et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2011, 82:638-642.
199. Svenningsson P., et al. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012, 11:697-707.
200. Tardif J.C. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?. J. Clin. Lipidol. 2010, 4:399-404.
201. Tardif J.C., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
202. Tashakori-Sabzevar F., et al. Crocetin attenuates spatial learning dysfunction and hippocampal injury in a model of vascular dementia. Curr. Neurovasc. Res. 2013, 10:325-334.
203. Tesseur I., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340. (924-e).
204. The T.G., et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014, 371:22-31.
205. Tian M., et al. Curcumin induces ABCA1 expression and apolipoprotein A-I-mediated cholesterol transmembrane in the chronic cerebral hypoperfusion aging rats. Am. J. Chin. Med. 2013, 41:1027-1042.
206. Ticozzi N., et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann. Neurol. 2010, 68:102-107.
207. Toth P.P., et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 2013, 7:484-525.
208. Tsai J.Y., et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc. Res. 2010, 88:415-423.
209. Tsuang D., et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013, 70:223-228.
210. Tunaru S., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 2003, 9:352-355.
211. Valdmanis P.N., et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology 2008, 71:514-520.
212. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
213. Valenza M., et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 2005, 25:9932-9939.
214. Valenza M., et al. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J. Neurosci. 2010, 30:10844-10850.
215. van Blitterswijk M., et al. Rare and common paraoxonase gene variants in amyotrophic lateral sclerosis patients. Neurobiol. Aging 2012, 33:1845. (e1-3).
216. van den Kommer T.N., et al. Role of lipoproteins and inflammation in cognitive decline: do they interact?. Neurobiol. Aging 2012, 33:196. (e1-12).
217. van Exel E., et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann. Neurol. 2002, 51:716-721.
218. Van Lenten B.J., et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 2007, 48:2344-2353.
219. Vance D.E., Vance J.E. Biochemistry of Lipids, Lipoproteins and Membranes 2008, Elsevier, Amsterdam, Boston.
220. Vanmierlo T., et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 2011, 32:1262-1272.
221. Veeraraghavalu K., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340. (924-f).
222. Verghese P.B., et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1807-E1816.
223. Vickers K.C., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
224. Vollbach H., et al. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann. Neurol. 2005, 58:436-441.
225. Wahrle S.E., et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 2004, 279:40987-40993.
226. Wahrle S.E., et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2005, 280:43236-43242.
227. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
228. Wang E.S., et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol. Scand. 2010, 122:350-359.
229. Weidner C., et al. Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice. Mol. Nutr. Food Res. 2014, 58:903-907.
230. Weinmann S., et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010, 10:14.
231. Wesson D.W., et al. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's beta-amyloidosis mouse model. J. Neurosci. 2011, 31:15962-15971.
232. Wexler N.S., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3498-3503.
233. Williams-Gray C.H., et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J. Neurol. 2009, 256:493-498.
234. Wolozin B. A fluid connection: cholesterol and Abeta. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5371-5373.
235. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2:a006346.
236. Yamada T., et al. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Acta Neuropathol. 1995, 90:633-636.
237. Yamauchi Y., et al. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J. Biol. Chem. 2003, 278:47890-47897.
238. Yao P., et al. Ginkgo biloba extract prevents ethanol induced dyslipidemia. Am. J. Chin. Med. 2007, 35:643-652.
239. Yin G.N., et al. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009, 1265:158-170.
240. Yoon M., et al. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng. Br. J. Pharmacol. 2003, 138:1295-1302.
241. Yu C., et al. Proposed mechanism for lipoprotein remodelling in the brain. Biochim. Biophys. Acta 2010, 1801:819-823.
242. Yu L., et al. The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease. Aging Cell 2012, 11:228-233.
243. Zelcer N., et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10601-10606.
244. Zhang X., et al. Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst 2012, 137:490-495.
245. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J. Hum. Genet. 2004, 49:474-481.
246. Zuliani G., et al. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65:559-564.